GetTopicDetailResponse(id=dfbc5e78c2, topicName=DDR, introduction=DDR, content=null, image=null, comments=1, allHits=569, url=https://h5.medsci.cn/topic?id=5778, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=71631, tagList=[TagDto(tagId=71631, tagName=DDR)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2259677, encodeId=fc3922596e789, content=<a href='/topic/show?id=dfbc5e78c2' target=_blank style='color:#2F92EE;'>#DDR#</a>在前列腺癌中，DNA損傷修復(fù)（DDR）途徑的基因突變，特別是同源重組修復(fù)（HRR）基因的突變，已成為治療的重要靶點。, objectTitle=Lancet Oncol | TALAPRO-2試驗結(jié)果：他拉唑帕尼聯(lián)合恩雜魯胺在轉(zhuǎn)移性去勢抵抗性前列腺癌患者中的生活質(zhì)量改善, objectType=article, longId=870966, objectId=e3328e096605, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240801/1722478199513_92910.jpg, objectUrl=/article/show_article.do?id=e3328e096605, replyNumber=0, likeNumber=26, createdTime=2025-04-08, rootId=0, userName=ms4000001513304915, userId=a1646442901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=廣東省, moduleDTOList=[ModuleDTO(moduleId=e3328e096605, moduleTitle=Lancet Oncol | TALAPRO-2試驗結(jié)果：他拉唑帕尼聯(lián)合恩雜魯胺在轉(zhuǎn)移性去勢抵抗性前列腺癌患者中的生活質(zhì)量改善, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=e3328e096605)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
